Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: 2026 ACC/AHA Guideline on the Management of Dyslipidemia … 2026 · sources last checked 2026-08-20

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Lipid / cholesterol selector

Choose the guideline lens, enter the prevention context, risk factors and LDL-C — get whether a statin is indicated, the LDL-C threshold/target, and the intensification ladder (statin → ezetimibe → PCSK9i → …), with each guideline’s year shown. The societies genuinely disagree on targets — switch the lens to compare.

Guideline lens

Prevention contextchoose one

Statin-indicated conditions

10-year CV risk (primary prevention)choose one

Use the calculator your guideline lens specifies (FRS / PREVENT / SCORE2 / QRISK3)

Current LDL-C (mmol/L)choose one

Current lipid therapychoose one

Triglycerides (mmol/L)choose one

Modifiers

Statin-indicated?

Assess risk

LDL-C threshold/target (low)

Intensify if LDL-C ≥ 2 mmol/L (or ApoB / non-HDL equivalent)

Suggested drug classesPer CCS 2021.

Enter the prevention context, risk and LDL-C to begin.

Switch the guideline lens to see the LDL-C target split — ESC/EAS <1.4, CCS threshold ≥1.8, ACC/AHA 2026 fixed goals, NICE %-reduction — change the recommendation.

Guidelines

References

  1. [1]Pearson GJ, et al. 2021 CCS Guidelines for the Management of Dyslipidemia for the Prevention of CVD in Adults. Can J Cardiol 2021;37:1129 (threshold-based; modified FRS; ApoB/non-HDL alternatives). link
  2. [2]NICE NG238 — Cardiovascular disease: risk assessment and reduction (atorvastatin 20/80; ≥40% non-HDL reduction; secondary LDL ≤2.0). 2023, amended 2025. link
  3. [3]2026 ACC/AHA Guideline on the Management of Dyslipidemia (reintroduces fixed LDL-C goals; PREVENT risk equation). Circulation 2026. VERIFY exact figures against the primary text. link
  4. [4]2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias (LDL targets unchanged: very-high <1.4, high <1.8; SCORE2). Eur Heart J 2025. link
  5. [5]USPSTF. Statin Use for the Primary Prevention of CVD in Adults: Preventive Medication. JAMA 2022 (statin initiation; no LDL target). link
  6. [6]Cannon CP, et al. IMPROVE-IT: Ezetimibe added to statin after ACS reduces events. NEJM 2015;372:2387. link
  7. [7]Ontario Drug Benefit e-Formulary — PCSK9 inhibitors and inclisiran are Limited Use with familial-hypercholesterolemia criteria (often stricter than the guideline threshold); ezetimibe LU 380/381. Verify live. link
  8. [8]Sabatine MS, et al. FOURIER (evolocumab); Schwartz GG, et al. ODYSSEY OUTCOMES (alirocumab): PCSK9 inhibitors reduce MACE on top of statin. NEJM 2017/2018. link
  9. [9]Nissen SE, et al. CLEAR Outcomes: Bempedoic acid in statin-intolerant patients (21% LDL-C↓, 13% MACE↓). NEJM 2023;388:1353. link
  10. [10]Bhatt DL, et al. REDUCE-IT: Icosapent ethyl for residual CV risk with elevated triglycerides on a statin. NEJM 2019;380:11. link